4 recruiting, 1 active not recruiting. 4 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 3, Active not recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
Follow Janux Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC JANX013, JANX007 - Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC) | Phase 1 | Recruiting | Janux Therapeutics | 110 | 2026-09-10 | 2026-09-17 |
| Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer JANX014 - Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Janux Therapeutics | 43 | 2026-04-15 | 2026-09-03 |
| Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability. JANX011 - Autoimmune | Early Phase 1 | Recruiting | Janux Therapeutics | 60 | 2026-02-16 | 2026-04-23 |
| Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies JANX008 - Non-Small Cell Lung Cancer, Renal Cell Carcinoma | Phase 1 | Active not recruiting | Janux Therapeutics | 130 | 2023-04-19 | 2026-06-01 |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) JANX007, Darolutamide - Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Janux Therapeutics | 272 | 2022-09-15 | 2026-10-29 |
Prostatic Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Prostatic Neoplasms, Castration-Resistant (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
darolutamide (1)
United States (4) · Australia (2) · Spain (1)